Dupilumab elicits a favorable response in type-2 inflammatory comorbidities of severe atopic dermatitis

Abstract

Abstract Background This case is the first report describing rapid, successful treatment of severe atopic dermatitis (AD) and comorbid type-2 inflammatory diseases in the same patient, with dupilumab treatment, with no side-effects. Case presentation We report on effects of dupilumab in a patient with severe AD, a long-standing history of a mild, perennial allergic rhino-conjunctivitis, moderate asthma and chronic rhinosinusitis with nasal polyps (CRSwNP). Conclusions Patients suffering from AD, asthma, allergic rhinitis and CRSwNP may be eligible for dupilumab single treatment that is possibly advantageous also from the pharmaco-economic standpoint.

Keywords

• Monoclonal antibody
• Precision medicine
• Asthma
• Nasal polyps
• Rhinoconjuctivitis